Reperfusion therapies of acute ischemic stroke: Potentials and failures

Frontiers in Neurology

Volumn 5, Issue NOV, 2014, Pages

  Tsivgoulis, Georgios ^a,b,c   Katsanos, Aristeidis H ^d   Alexandrov, Andrei V ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c ST ANNE S UNIVERSITY HOSPITAL   (Czech Republic)

^d UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Cerebral ischemia; Intra arterial; Intravenous; Reperfusion therapies; Sonothrombolysis; Stroke; Thrombolysis

Indexed keywords

EID: 84949116615     PISSN: None     EISSN: 16642295     Source Type: Journal    
DOI: 10.3389/fneur.2014.00215     Document Type: Review

References (97)

1. Fisher M. Acute ischemic stroke therapy: current status and future directions. Expert Rev Cardiovasc Ther (2013) 11(9):1097-9. doi: 10.1586/14779072.2013.827450
2. Hill MD, Hachinski V. Stroke treatment: time is brain. Lancet (1998) 352(Suppl 3):SIII10-4. doi:10.1016/S0140-6736(98)90088-5
3. National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med (1995) 333(24):1581-7. doi:10.1056/NEJM199512143332401
4. Haley EC Jr, Thompson JL, Grotta JC, Lyden PD, Hemmen TG, Brown DL, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke (2010) 41(4):707-11. doi:10.1161/STROKEAHA.109.572040
5. Parsons M, Spratt N, Bivard A, Campbell B, Chung K, Miteff F, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med (2012) 366(12):1099-107. doi:10.1056/NEJMoa1109842
6. Hacke W, Albers G, Al-Rawi Y, Bogousslavsky J, Davalos A, Eliasziw M, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke (2005) 36(1):66-73. doi:10.1161/01.STR.0000149938.08731.2c
7. Hacke W, Furlan AJ, Al-Rawi Y, Davalos A, Fiebach JB, Gruber F, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol (2009) 8(2):141-50. doi:10.1016/S1474-4422(08)70267-9
8. Alexandrov AV, Molina CA, Grotta JC, Garami Z, Ford SR, Alvarez-Sabin J, et al. Ultrasound-enhanced systemic thrombolysis for acute ischemic stroke. N Engl J Med (2004) 351(21):2170-8. doi:10.1056/NEJMoa041175
9. Molina CA, Barreto AD, Tsivgoulis G, Sierzenski P, Malkoff MD, Rubiera M, et al. Transcranial ultrasound in clinical sonothrombolysis (TUCSON) trial. Ann Neurol (2009) 66(1):28-38. doi:10.1002/ana.21723
10. Broderick JP, Palesch YY, Demchuk AM, Yeatts SD, Khatri P, Hill MD, et al. Endovascular therapy after intravenous t-PA versus t-PA alone for stroke. N Engl J Med (2013) 368(10):893-903. doi:10.1056/NEJMoa1214300
11. Furlan A, Higashida R, Wechsler L, Gent M, Rowley H, Kase C, et al. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: a randomized controlled trial. Prolyse in acute cerebral thromboembolism. JAMA (1999) 282(21):2003-11. doi:10.1001/jama.282.21.2003
12. Smith WS, Sung G, Starkman S, Saver JL, Kidwell CS, Gobin YP, et al. Safety and efficacy of mechanical embolectomy in acute ischemic stroke: results of the MERCI trial. Stroke (2005) 36(7):1432-8. doi:10.1161/01.STR.0000171066.25248.1d
13. Smith WS, Sung G, Saver J, Budzik R, Duckwiler G, Liebeskind DS, et al. Mechanical thrombectomy for acute ischemic stroke: final results of the multi MERCI trial. Stroke (2008) 39(4):1205-12. doi:10.1161/STROKEAHA.107.497115
14. Penumbra Pivotal Stroke Trial Investigators. The penumbra pivotal stroke trial: safety and effectiveness of a new generation of mechanical devices for clot removal in intracranial large vessel occlusive disease. Stroke (2009) 40(8):2761-8. doi:10.1161/STROKEAHA.108.544957
15. Tarr R, Hsu D, Kulcsar Z, Bonvin C, Rufenacht D, Alfke K, et al. The post trial: initial post-market experience of the Penumbra system: revascularization of large vessel occlusion in acute ischemic stroke in the United States and Europe. J Neurointerv Surg (2010) 2(4):341-4. doi:10.1136/jnis.2010.002600
16. Saver JL, Jahan R, Levy EI, Jovin TG, Baxter B, Nogueira RG, et al. Solitaire flow restoration device versus the Merci retriever in patients with acute ischaemic stroke (SWIFT): a randomised, parallel-group, non-inferiority trial. Lancet (2012) 380(9849):1241-9. doi:10.1016/S0140-6736(12)61384-1
17. Nogueira RG, Lutsep HL, Gupta R, Jovin TG, Albers GW, Walker GA, et al. Trevo versus Merci retrievers for thrombectomy revascularisation of large vessel occlusions in acute ischaemic stroke (TREVO 2): a randomised trial. Lancet (2012) 380(9849):1231-40. doi:10.1016/S0140-6736(12)61299-9
18. Kidwell CS, Jahan R, Gornbein J, Alger JR, Nenov V, Ajani Z, et al. A trial of imaging selection and endovascular treatment for ischemic stroke. N Engl J Med (2013) 368(10):914-23. doi:10.1056/NEJMoa1212793
19. Ciccone A, Valvassori L, Nichelatti M, Sgoifo A, Ponzio M, Sterzi R, et al. Endovascular treatment for acute ischemic stroke. N Engl J Med (2013) 368(10):904-13. doi:10.1056/NEJMoa1213701
20. Lowe G. The pharmacology of thrombolytic and fibrinogen-depleting agents in the treatment of acute ischaemic stroke. Cerebrovasc Dis (1998) 8(Suppl 1):36-42. doi:10.1159/000047503
21. Sherman DG, Atkinson RP, Chippendale T, Levin KA, Ng K, Futrell N, et al. Intravenous ancrod for treatment of acute ischemic stroke: the STAT study: a randomized controlled trial. Stroke Treatment with Ancrod Trial. JAMA (2000) 283(18):2395-403. doi:10.1001/jama.283.18.2395
22. Hennerici MG, Kay R, Bogousslavsky J, Lenzi GL, Verstraete M, Orgogozo JM. Intravenous ancrod for acute ischaemic stroke in the European stroke treatment with ancrod trial: a randomised controlled trial. Lancet (2006) 368(9550):1871-8. doi:10.1016/S0140-6736(06)69776-6
23. Hao Z, Liu M, Counsell C, Wardlaw JM, Lin S, Zhao X. Fibrinogen depleting agents for acute ischaemic stroke. Cochrane Database Syst Rev (2012) 3:CD000091. doi:10.1002/14651858.CD000091.pub2
24. Multicentre Acute Stroke Trial-Italy (MAST-I) Group. Randomised controlled trial of streptokinase, aspirin, and combination of both in treatment of acute ischaemic stroke. Lancet (1995) 346(8989):1509-14. doi:10.1016/S0140-6736(95)92049-8
25. Multicenter Acute Stroke Trial-Europe Study Group. Thrombolytic therapy with streptokinase in acute ischemic stroke. N Engl J Med (1996) 335(3):145-50. doi:10.1056/NEJM199607183350301
26. Donnan GA, Davis SM, Chambers BR, Gates PC, Hankey GJ, McNeil JJ, et al. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian streptokinase (ASK) trial study group. JAMA (1996) 276(12):961-6. doi:10.1001/jama.276.12.961
27. Jauch EC, Saver JL, Adams HP Jr, Bruno A, Connors JJ, Demaerschalk BM, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American heart association/American stroke association. Stroke (2013) 44(3):870-947. doi:10.1161/STR.0b013e318284056a
28. European Stroke Organisation (ESO) Executive Committee, ESO Writing Committee. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis (2008) 25(5):457-507. doi:10.1159/000131083
29. Lisabeth LD, Brown DL, Morgenstern LB. Barriers to intravenous tissue plasminogen activator for acute stroke therapy in women. Gend Med (2006) 3(4):270-8. doi:10.1016/S1550-8579(06)80215-9
30. Manawadu D, Bodla S, Jarosz J, Keep J, Kalra L. A case-controlled comparison of thrombolysis outcomes between wake-up and known time of onset ischemic stroke patients. Stroke (2013) 44(8):2226-31. doi:10.1161/STROKEAHA.111.000757
31. Manawadu D, Bodla S, Keep J, Jarosz J, Kalra L. An observational study of thrombolysis outcomes in wake-up ischemic stroke patients. Stroke (2013) 44(2):427-31. doi:10.1161/STROKEAHA.112.673145
32. Labiche LA, Malkoff M, Alexandrov AV. Residual flow signals predict complete recanalization in stroke patients treated with TPA. J Neuroimaging (2003) 13(1):28-33. doi:10.1111/j.1552-6569.2003.tb00153.x
33. Saqqur M, Uchino K, Demchuk AM, Molina CA, Garami Z, Calleja S, et al. Site of arterial occlusion identified by transcranial Doppler predicts the response to intravenous thrombolysis for stroke. Stroke (2007) 38(3):948-54. doi:10.1161/01.STR.0000257304.21967.ba
34. Christou I, Felberg RA, Demchuk AM, Burgin WS, Malkoff M, Grotta JC, et al. Intravenous tissue plasminogen activator and flow improvement in acute ischemic stroke patients with internal carotid artery occlusion. J Neuroimaging (2002) 12(2):119-23. doi:10.1111/j.1552-6569.2002.tb00107.x
35. Marler JR, Tilley BC, Lu M, Brott TG, Lyden PC, Grotta JC, et al. Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 55(11):1649-55. doi:10.1212/WNL.55.11.1649
36. Alexandrov AV, Burgin WS, Demchuk AM, El-Mitwalli A, Grotta JC. Speed of intracranial clot lysis with intravenous tissue plasminogen activator therapy: sonographic classification and short-term improvement. Circulation (2001) 103(24):2897-902. doi:10.1161/01.CIR.103.24.2897
37. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, et al. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet (2004) 363(9411):768-74. doi:10.1016/S0140-6736(04)15692-4
38. Hacke W, Kaste M, Bluhmki E, Brozman M, Davalos A, Guidetti D, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med (2008) 359(13):1317-29. doi:10.1056/NEJMoa0804656
39. Wahlgren N, Ahmed N, Davalos A, Hacke W, Millan M, Muir K, et al. Thrombolysis with alteplase 3-4.5 h after acute ischaemic stroke (SITS-ISTR): an observational study. Lancet (2008) 372(9646):1303-9. doi:10.1016/S0140-6736(08)61339-2
40. Davis SM, Donnan GA, Parsons MW, Levi C, Butcher KS, Peeters A, et al. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol (2008) 7(4):299-309. doi:10.1016/S1474-4422(08)70044-9
41. Rha JH, Saver JL. The impact of recanalization on ischemic stroke outcome: a meta-analysis. Stroke (2007) 38(3):967-73. doi:10.1161/01.STR.0000258112.14918.24
42. Saqqur M, Tsivgoulis G, Molina CA, Demchuk AM, Garami Z, Barreto A, et al. Design of a prospective multi-national CLOTBUST collaboration on reperfusion therapies for stroke (CLOTBUST-PRO). Int J Stroke (2008) 3(1):66-72. doi:10.1111/j.1747-4949.2008.00167.x
43. Balami JS, Chen R, Sutherland BA, Buchan AM. Thrombolytic agents for acute ischaemic stroke treatment: the past, present and future. CNS Neurol Disord Drug Targets (2013) 12(2):145-54. doi:10.2174/18715273113129990057
44. Rother J, Ford GA, Thijs VN. Thrombolytics in acute ischaemic stroke: historical perspective and future opportunities. Cerebrovasc Dis (2013) 35(4):313-9. doi:10.1159/000348705
45. Martinez-Sanchez P, Diez-Tejedor E, Fuentes B, Ortega-Casarrubios MA, Hacke W. Systemic reperfusion therapy in acute ischemic stroke. Cerebrovasc Dis (2007) 24(Suppl 1):143-52. doi:10.1159/000107390
46. Bivard A, Lin L, Parsonsb MW. Review of stroke thrombolytics. J Stroke (2013) 15(2):90-8. doi:10.5853/jos.2013.15.2.90
47. Behrouz R. Intravenous tenecteplase in acute ischemic stroke: an updated review. J Neurol (2014) 261(6):1069-72. doi:10.1007/s00415-013-7102-0
48. Tsivgoulis G, Alleman J, Katsanos AH, Barreto AD, Kohrmann M, Schellinger PD, et al. Comparative efficacy of different acute reperfusion therapies for acute ischemic stroke: a comprehensive benefit-risk analysis of clinical trials. Brain Behav (2014). doi:10.1002/brb3.279
49. Liberatore GT, Samson A, Bladin C, Schleuning WD, Medcalf RL. Vampire bat salivary plasminogen activator (desmoteplase): a unique fibrinolytic enzyme that does not promote neurodegeneration. Stroke (2003) 34(2):537-43. doi:10.1161/01.STR.0000049764.49162.76
50. Reddrop C, Moldrich RX, Beart PM, Farso M, Liberatore GT, Howells DW, et al. Vampire bat salivary plasminogen activator (desmoteplase) inhibits tissue-type plasminogen activator-induced potentiation of excitotoxic injury. Stroke (2005) 36(6):1241-6. doi:10.1161/01.STR.0000166050.84056.48
51. Blinc A, Francis CW, Trudnowski JL, Carstensen EL. Characterization of ultrasound-potentiated fibrinolysis in vitro. Blood (1993) 81(10):2636-43.
52. Kimura M, Iijima S, Kobayashi K, Furuhata H. Evaluation of the thrombolytic effect of tissue-type plasminogen activator with ultrasonic irradiation: in vitro experiment involving assay of the fibrin degradation products from the clot. Biol Pharm Bull (1994) 17(1):126-30. doi:10.1248/bpb.17.126
53. Alexandrov AV, Demchuk AM, Felberg RA, Christou I, Barber PA, Burgin WS, et al. High rate of complete recanalization and dramatic clinical recovery during tPA infusion when continuously monitored with 2-MHz transcranial Doppler monitoring. Stroke (2000) 31(3):610-4. doi:10.1161/01.STR.31.3.610
54. Alexandrov AV. Ultrasound enhanced thrombolysis for stroke. Int J Stroke (2006) 1(1):26-9. doi:10.1111/j.1747-4949.2005.00012.x
55. Alexandrov AV, Barlinn K. Taboos and opportunities in sonothrombolysis for stroke. Int J Hyperthermia (2012) 28(4):397-404. doi:10.3109/02656736.2012.674621
56. Rubiera M, Alexandrov AV. Sonothrombolysis in the management of acute ischemic stroke. Am J Cardiovasc Drugs (2010) 10(1):5-10. doi:10.2165/11316850-000000000-00000
57. Tsivgoulis G, Eggers J, Ribo M, Perren F, Saqqur M, Rubiera M, et al. Safety and efficacy of ultrasound-enhanced thrombolysis: a comprehensive review and meta-analysis of randomized and nonrandomized studies. Stroke (2010) 41(2):280-7. doi:10.1161/STROKEAHA.109.563304
58. Ricci S, Dinia L, Del Sette M, Anzola P, Mazzoli T, Cenciarelli S, et al. Sonothrombolysis for acute ischaemic stroke. Cochrane Database Syst Rev (2012) 10:CD008348. doi:10.1002/14651858.CD008348.pub3
59. Saqqur M, Tsivgoulis G, Nicoli F, Skoloudik D, Sharma VK, Larrue V, et al. The role of sonolysis and sonothrombolysis in acute ischemic stroke: a systematic review and meta-analysis of randomized controlled trials and case-control studies. J Neuroimaging (2014) 24(3):209-20. doi:10.1111/jon.12026
60. Daffertshofer M, Gass A, Ringleb P, Sitzer M, Sliwka U, Els T, et al. Transcranial low-frequency ultrasound-mediated thrombolysis in brain ischemia: increased risk of hemorrhage with combined ultrasound and tissue plasminogen activator: results of a phase II clinical trial. Stroke (2005) 36(7):1441-6. doi:10.1161/01.STR.0000170707.86793.1a
61. Rubiera M, Ribo M, Delgado-Mederos R, Santamarina E, Maisterra O, Delgado P, et al. Do bubble characteristics affect recanalization in stroke patients treated with microbubble-enhanced sonothrombolysis? Ultrasound Med Biol (2008) 34(10):1573-7. doi:10.1016/j.ultrasmedbio.2008.02.011
62. Perren F, Loulidi J, Poglia D, Landis T, Sztajzel R. Microbubble potentiated transcranial duplex ultrasound enhances IV thrombolysis in acute stroke. J Thromb Thrombolysis (2008) 25(2):219-23. doi:10.1007/s11239-007-0044-6
63. Alexandrov AV, Mikulik R, Ribo M, Sharma VK, Lao AY, Tsivgoulis G, et al. A pilot randomized clinical safety study of sonothrombolysis augmentation with ultrasound-activated perflutren-lipid microspheres for acute ischemic stroke. Stroke (2008) 39(5):1464-9. doi:10.1161/STROKEAHA.107.505727
64. Alexandrov AV. Ultrasound enhancement of fibrinolysis. Stroke (2009) 40(3 Suppl):S107-10. doi:10.1161/STROKEAHA.108.530931
65. Xie F, Tsutsui JM, Lof J, Unger EC, Johanning J, Culp WC, et al. Effectiveness of lipid microbubbles and ultrasound in declotting thrombosis. Ultrasound Med Biol (2005) 31(7):979-85. doi:10.1016/j.ultrasmedbio.2005.03.008
66. Culp WC, Porter TR, Lowery J, Xie F, Roberson PK, Marky L. Intracranial clot lysis with intravenous microbubbles and transcranial ultrasound in swine. Stroke (2004) 35(10):2407-11. doi:10.1161/01.STR.0000140890.86779.79
67. Sharma VK, Tsivgoulis G, Lao AY, Malkoff MD, Alexandrov AW, Alexandrov AV. Quantification of microspheres appearance in brain vessels: implications for residual flow velocity measurements, dose calculations, and potential drug delivery. Stroke (2008) 39(5):1476-81. doi:10.1161/STROKEAHA.107.501593
68. Barreto AD, Sharma VK, Lao AY, Schellinger PD, Amarenco P, Sierzenski P, et al. Safety and dose-escalation study design of transcranial ultrasound in clinical SONolysis for acute ischemic stroke: the TUCSON trial. Int J Stroke (2009) 4(1):42-8. doi:10.1111/j.1747-4949.2009.00252.x
69. Tsivgoulis G, Alexandrov AV, Sloan MA. Advances in transcranial Doppler ultrasonography. Curr Neurol Neurosci Rep (2009) 9(1):46-54. doi:10.1007/s11910-009-0008-7
70. Tsivgoulis G, Culp WC, Alexandrov AV. Ultrasound enhanced thrombolysis in acute arterial ischemia. Ultrasonics (2008) 48(4):303-11. doi:10.1016/j.ultras.2007.11.008
71. Tsivgoulis G, Alexandrov A. Ultrasound-enhanced thrombolysis: from bedside to bench. Stroke (2008) 39(5):1404-5. doi:10.1161/STROKEAHA.107.505594
72. Barreto AD, Alexandrov AV, Shen L, Sisson A, Bursaw AW, Sahota P, et al. CLOTBUST-hands free: pilot safety study of a novel operator-independent ultrasound device in patients with acute ischemic stroke. Stroke (2013) 44(12):3376-81. doi:10.1161/STROKEAHA.113.002713
73. Barlinn K, Barreto AD, Sisson A, Liebeskind DS, Schafer ME, Alleman J, et al. CLOTBUST-hands free: initial safety testing of a novel operator-independent ultrasound device in stroke-free volunteers. Stroke (2013) 44(6):1641-6. doi:10.1161/STROKEAHA.113.001122
74. Rudd AG, Hoffman A, Grant R, Campbell JT, Lowe D. Stroke thrombolysis in England, Wales and Northern Ireland: how much do we do and how much do we need? J Neurol Neurosurg Psychiatry (2011) 82(1):14-9. doi:10.1136/jnnp.2009.203174
75. Balami JS, Sutherland BA, Buchan AM. Complications associated with recombinant tissue plasminogen activator therapy for acute ischaemic stroke. CNS Neurol Disord Drug Targets (2013) 12(2):155-69. doi:10.2174/18715273112119990050
76. del Zoppo GJ, Higashida RT, Furlan AJ, Pessin MS, Rowley HA, Gent M. PROACT: a phase II randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. PROACT investigators. Prolyse in acute cerebral thromboembolism. Stroke (1998) 29(1):4-11. doi:10.1161/01.STR.29.1.4
77. O'Rourke K, Berge E, Walsh CD, Kelly PJ. Percutaneous vascular interventions for acute ischaemic stroke. Cochrane Database Syst Rev (2010) (10):CD007574. doi:10.1002/14651858.CD007574.pub2
78. IMS Study Investigators. Combined intravenous and intra-arterial recanalization for acute ischemic stroke: the interventional management of stroke study. Stroke (2004) 35(4):904-11. doi:10.1161/01.STR.0000121641.77121.98
79. IMS Study Investigators. The interventional management of stroke (IMS) II study. Stroke (2007) 38(7):2127-35. doi:10.1161/STROKEAHA.107.483131
80. Khatri P, Hill MD, Palesch YY, Spilker J, Jauch EC, Carrozzella JA, et al. Methodology of the interventional management of stroke III trial. Int J Stroke (2008) 3(2):130-7. doi:10.1111/j.1747-4949.2008.00151.x
81. Yeatts SD, Martin RH, Coffey CS, Lyden PD, Foster LD, Woolson RF, et al. Challenges of decision making regarding futility in a randomized trial: the interventional management of stroke III experience. Stroke (2014) 45(5):1408-14. doi:10.1161/STROKEAHA.113.003925
82. Demchuk AM, Goyal M, Yeatts SD, Carrozzella J, Foster LD, Qazi E, et al. Recanalization and clinical outcome of occlusion sites at baseline CT angiography in the interventional management of stroke III trial. Radiology (2014) 273(1):202-10. doi:10.1148/radiol.14132649
83. Khatri P, Yeatts SD, Mazighi M, Broderick JP, Liebeskind DS, Demchuk AM, et al. Time to angiographic reperfusion and clinical outcome after acute ischaemic stroke: an analysis of data from the interventional management of stroke (IMS III) phase 3 trial. Lancet Neurol (2014) 13(6):567-74. doi:10.1016/S1474-4422(14)70066-3
84. Wardlaw JM, Koumellis P, Liu M. Thrombolysis (different doses, routes of administration and agents) for acute ischaemic stroke. Cochrane Database Syst Rev (2013) 5:CD000514. doi:10.1002/14651858.CD000514.pub3
85. Becker KJ, Brott TG. Approval of the MERCI clot retriever: a critical view. Stroke (2005) 36(2):400-3. doi:10.1161/01.STR.0000153056.25397.ff
86. Bose A, Henkes H, Alfke K, Reith W, Mayer TE, Berlis A, et al. The Penumbra system: a mechanical device for the treatment of acute stroke due to thromboembolism. AJNR Am J Neuroradiol (2008) 29(7):1409-13. doi:10.3174/ajnr.A1110
87. Alexandrov AV, Schellinger PD, Saqqur M, Barreto A, Demchuk AM, Ribo M, et al. Reperfusion and outcomes in Penumbra vs. systemic tissue plasminogen activator clinical trials. Int J Stroke (2011) 6(2):118-22. doi:10.1111/j.1747-4949.2010.00559.x
88. Leker RR, Eichel R, Gomori JM, Ramirez de Noriega F, Ben-Hur T, Cohen JE. Stent-based thrombectomy versus intravenous tissue plasminogen activator in patients with acute middle cerebral artery occlusion. Stroke (2012) 43(12):3389-91. doi:10.1161/STROKEAHA.112.673665
89. Koh JS, Lee SJ, Ryu CW, Kim HS. Safety and efficacy of mechanical thrombectomy with solitaire stent retrieval for acute ischemic stroke: a systematic review. Neurointervention (2012) 7(1):1-9. doi:10.5469/neuroint.2012.7.1.1
90. Qureshi AI, Abd-Allah F, Aleu A, Connors JJ, Hanel RA, Hassan AE, et al. Endovascular treatment for acute ischemic stroke patients: implications and interpretation of IMS III, MR rescue, and synthesis expansion trials: a report from the working group of international congress of interventional neurology. J Vasc Interv Neurol (2014) 7(1):56-75.
91. Hinduja A. Imaging predictors of outcome following intravenous thrombolysis in acute stroke. Acta Neurol Belg (2014) 114(2):81-6. doi:10.1007/s13760-013-0270-y
92. Abilleira S, Cardona P, Ribo M, Millan M, Obach V, Roquer J, et al. Outcomes of a contemporary cohort of 536 consecutive patients with acute ischemic stroke treated with endovascular therapy. Stroke (2014) 45(4):1046-52. doi:10.1161/STROKEAHA.113.003489
93. Kurre W, Aguilar-Perez M, Niehaus L, Fischer S, Schmid E, Bazner H, et al. Predictors of outcome after mechanical thrombectomy for anterior circulation large vessel occlusion in patients aged =80 years. Cerebrovasc Dis (2013) 36(5-6):430-6. doi:10.1159/000356186
94. Kappelhof M, Marquering HA, Berkhemer OA, Majoie CB. Intra-arterial treatment of patients with acute ischemic stroke and internal carotid artery occlusion: a literature review. J Neurointerv Surg (2014). doi:10.1136/neurintsurg-2013-011004
95. Nagel S, Kellert L, Mohlenbruch M, Bosel J, Rohde S, Ringleb P. Improved clinical outcome after acute basilar artery occlusion since the introduction of endovascular thrombectomy devices. Cerebrovasc Dis (2013) 36(5-6):394-400. doi:10.1159/000356185
96. Fesl G, Holtmannspoetter M, Patzig M, Mayer TE, Pfefferkorn T, Brueckmann H, et al. Mechanical thrombectomy in basilar artery thrombosis: technical advances and safety in a 10-year experience. Cardiovasc Intervent Radiol (2014) 37(2):355-61. doi:10.1007/s00270-013-0827-4
97. Ciccone A, del Zoppo GJ. Evolving role of endovascular treatment of acute ischemic stroke. Curr Neurol Neurosci Rep (2014) 14(1):416. doi:10.1007/s11910-013-0416-6